$14.25
0.080.56%
At Close: -
$14.25
00.00%
After Hours: 4:04 PM EDT
15 minutes delayed
Entrada Therapeutics
TRDANASDAQ
Entrada Therapeutics (NASDAQ:TRDA) Stock, Analyst Ratings, Price Targets, Predictions
Entrada Therapeutics Inc has a consensus price target of $11.6, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Oppenheimer on June 25, 2024, March 18, 2024, and January 5, 2024. With an average price target of $20 between HC Wainwright & Co., HC Wainwright & Co., and Oppenheimer, there's an implied 40.35% upside for Entrada Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Goldman Sachs
Evercore ISI Group
Cowen & Co.
1calculated from analyst ratings
Analyst Ratings for Entrada Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2024 | Buy Now | 26.32% | HC Wainwright & Co. | Raghuram Selvaraju | $20 → $18 | Maintains | Buy | Get Alert |
| 03/18/2024 | Buy Now | 40.35% | HC Wainwright & Co. | Raghuram Selvaraju | → $20 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | 54.39% | Oppenheimer | Hartaj Singh | → $22 | Initiates | → Outperform | Get Alert |
| 11/27/2023 | Buy Now | 40.35% | HC Wainwright & Co. | Raghuram Selvaraju | $25 → $20 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | 75.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 75.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 75.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 75.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 75.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $25 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 26.32% | Goldman Sachs | Chris Shibutani | $13 → $18 | Maintains | Neutral | Get Alert |
| 08/16/2022 | Buy Now | -8.77% | Goldman Sachs | Chris Shibutani | $10 → $13 | Maintains | Neutral | Get Alert |
| 05/24/2022 | Buy Now | -29.82% | Goldman Sachs | Chris Shibutani | $22 → $10 | Maintains | Neutral | Get Alert |
| 11/24/2021 | Buy Now | — | Evercore ISI Group | Jonathan Miller | — | Initiates | → Outperform | Get Alert |
| 11/23/2021 | Buy Now | — | Cowen & Co. | Joseph Thome | — | Initiates | → Outperform | Get Alert |
| 11/23/2021 | Buy Now | 103.51% | Goldman Sachs | Chris Shibutani | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Entrada Therapeutics (TRDA) stock?
The latest price target for Entrada Therapeutics (NASDAQ:TRDA) was reported by HC Wainwright & Co. on June 25, 2024. The analyst firm set a price target for $18.00 expecting TRDA to rise to within 12 months (a possible 26.32% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
The latest analyst rating for Entrada Therapeutics (NASDAQ:TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics maintained their buy rating.
When was the last upgrade for Entrada Therapeutics (TRDA)?
There is no last upgrade for Entrada Therapeutics
When was the last downgrade for Entrada Therapeutics (TRDA)?
There is no last downgrade for Entrada Therapeutics.
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a maintained with a price target of $20.00 to $18.00. The current price Entrada Therapeutics (TRDA) is trading at is $14.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.